Beam Therapeutics
BEAM
231 hedge funds and large institutions have $3.93B invested in Beam Therapeutics in 2021 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 99 increasing their positions, 45 reducing their positions, and 38 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 45
3% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 38
0% more funds holding
Funds holding: 231 → 231 (0)
4.59% less ownership
Funds ownership: 72.68% → 68.09% (-4.6%)
18% less call options, than puts
Call options by funds: $22M | Put options by funds: $26.8M
33% less capital invested
Capital invested by funds: $5.85B → $3.93B (-$1.92B)
64% less funds holding in top 10
Funds holding in top 10: 11 → 4 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$109M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$71.8M |
| 3 |
Goldman Sachs
New York
|
+$39.8M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$38.2M |
| 5 |
BlackRock
New York
|
+$34.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$378M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$39.9M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
-$31.5M |
| 4 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$28.9M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$22.3M |
BEAM Hedge Fund Activity: Q3 2021 in Review
231 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q3 2021, worth a combined $3.93B — down 33% from $5.85B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new BEAM positions and 38 closed out — a net gain of 1 holder — while 99 added to existing stakes and 45 trimmed.
The largest buyer was Vanguard Group, adding an estimated $109M. The largest seller was Fidelity Investments, cutting an estimated $378M.
- 231 institutional investors held Beam Therapeutics (BEAM) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $3.93B of Beam Therapeutics stock for Q3 2021, down 33% quarter-over-quarter.
- 39 funds opened new Beam Therapeutics positions in Q3 2021 and 38 closed out, a net change of +1 holder.
- The largest Beam Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $109M added.
- The largest Beam Therapeutics seller in Q3 2021 was Fidelity Investments, an estimated $378M sold.
Based on aggregated 13F filings for Q3 2021.